DDInter1929 DDInter856
Verteporfin, marketed as Visudyne, is a benzoporphyrin derivative. It is used as a photosensitizer in photodynamic therapy to eliminate abnormal blood vessels in wet form macular degeneration. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 nm in the presence of oxygen, produces highly reactive short-lived singlet oxygen and other reactive oxygen radicals, resulting in local damage to the endothelium and blockage of the vessels.
Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (factor IIa) and factor Xa. UH is different from low molecular weight heparin (LMWH) in the following ways: the average molecular weight of LMWH is about 4.5 kDa whereas it is 15 kDa for UH; UH requires continuous infusions; activated partial prothrombin time (aPTT) monitoring is required when using UH; and UH has a higher risk of bleeding and higher risk of osteoporosis in long term use. Unfractionated heparin is more specific than LMWH for thrombin. Furthermore, the effects of UH can typically be reversed by using protamine sulfate.
Verteporfin {u} (Compound) is included by {v} (Pharmacologic Class) Photosensitizing Activity
Verteporfin {u} (Compound) causes {v} (Side Effect) Injection site pain
Verteporfin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Polymyxin B
Verteporfin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lapatinib
Verteporfin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bivalirudin
Verteporfin {u} may lead to a major life threatening interaction when taken with {v} Aminolevulinic acid
Verteporfin (Compound) is included by Photosensitizing Activity (Pharmacologic Class)
Verteporfin (Compound) causes Injection site pain (Side Effect)
Verteporfin may cause a minor interaction that can limit clinical effects when taken with Polymyxin B
Verteporfin may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib
Verteporfin may cause a moderate interaction that could exacerbate diseases when taken with Bivalirudin
Verteporfin may lead to a major life threatening interaction when taken with Aminolevulinic acid